Earnings Releases·Nov 5, 2026, 4:03 PM ET

Biodesix — Third Quarter 2026 Earnings Summary

Total revenue rose 10% year-over-year to $24.0 million, driven by a 16% increase in Diagnostic Testing revenue to $23.0 million, while Net loss narrowed 8% to $8.0 million and Adjusted EBITDA loss improved 16% to $3.9 million.
Full-year 2026 revenue guidance was raised to $101 million–$103 million (midpoint ~15% growth), with the company maintaining a gross margin target of approximately 80% and reporting cash and cash equivalents of $28.4 million.
Strategic portfolio expansion includes the addition of Digital Diagnostics to create a multimodal platform and the announcement of two complementary Molecular Residual Disease (MRD) monitoring programs developed with Bio-Rad Laboratories and Thermo Fisher Scientific.
Management acknowledged Q3 growth fell short of expectations due to sales force sizing and seasonality but noted corrective actions have been taken, positioning the firm for improved execution in Q4 and 2027.
Stockholders' equity turned positive to $8.7 million from a $2.5 million deficit in December 2025, while share count increased to 11.05 million following $6.3 million in net proceeds from an at-the-market program.